Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody

#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody

Published

on

Biogen trumpeted new Phase 2 lupus data on Saturday for a program it hopes will become a pillar of its immunology pipeline.

The drug litifilimab improved patients’ skin lesions after 24 weeks, with 14.7% reaching …​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Vertex’s biggest overhang: a rival 50 times smaller

Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics “looms large” over Vertex.

Read More

Published

on

Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics “looms large” over Vertex.

Read More

Continue Reading

Uncategorized

Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss

Published

on

The anti-TL1A antibody from Merck’s 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.

Continue Reading

Uncategorized

BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine

Published

on

Lower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.

Continue Reading
Advertisement

Trending